NGENF (NervGen Pharma) Common Stock : $59.43 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Common Stock?

NervGen Pharma's quarterly common stock declined from Mar. 2024 ($58.94 Mil) to Jun. 2024 ($58.40 Mil) but then increased from Jun. 2024 ($58.40 Mil) to Sep. 2024 ($59.43 Mil).

NervGen Pharma's annual common stock increased from Dec. 2021 ($33.13 Mil) to Dec. 2022 ($42.26 Mil) and increased from Dec. 2022 ($42.26 Mil) to Dec. 2023 ($43.93 Mil).

NervGen Pharma Common Stock Historical Data

The historical data trend for NervGen Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Common Stock Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

11.61

17.92

33.13

42.26

43.93

NervGen Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															43.43	43.93	58.94	58.40	59.43

NervGen Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

NervGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (OTCPK:NGENF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

9UA:Germany NGEN:Canada

Address

112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4

Website

https://www.nervgen.com

NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

NervGen Pharma Headlines

From GuruFocus

NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th

By PRNewswire PRNewswire • 07-09-2019